Recombinant Human Granulocyte ColonyStimulating Market
Recombinant Human Granulocyte Colony-
Stimulating Market Scope: Industry Analysis, Market
Size, Growth, Trends Till 2031
Request Sample Report
Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth
The recombinant human granulocyte colony-stimulating factor market is poised for growth, driven by rising demand for hematopoietic growth factors in cancer treatment and bone marrow disorders. The global market is projected to reach approximately $XX billion by 2027, reflecting increased adoption in healthcare systems and advancements in biotechnology.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Amgen
◍ Qilu Pharmaceutical
◍ Shijiazhuang Pharmaceutical
◍ Kyowa Hakko Kirin
◍ Gensci
◍ Amoytop Biotech
◍ Hangzhou Jiuyuan
◍ Huaxin
◍ Triprime
◍ Sinovac
◍ Zhaoke
◍ Kawin
The Recombinant Human Granulocyte ColonyStimulating Market features key players like Amgen, Qilu Pharmaceutical, and Kyowa Hakko Kirin, focusing on innovative therapies for neutropenia. Their R&D investments and global distribution networks drive market growth. Sales revenues of select companies include Amgen's approximately $7 billion from G-CSF products and Gensci's $300 million. Request Sample Report
Market Segmentation
By Application
◍ Chemotherapy Induced Neutropenia
◍ Before Blood Donation
◍ Stem Cell Transplants
◍ Others
By Product
◍ Lenograstim (Granocyte)
◍ Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
◍ Others
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
